SCENESSE® treatment in Europe

17 May 2016

German Porphyria Expert Centres to start distribution of SCENESSE® (afamelanotide 16mg)

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced an update on the company’s post-authorisation distribution of SCENESSE® (afamelanotide 16mg) across Europe for adult patients with the rare disorder erythropoietic protoporphyria (EPP).

Download PDF for more

We use cookies to give you the best experience.